Source link : https://newshealth.biz/health-news/semaglutide-shows-benefits-for-pad-across-t2d-subgroups/
CHICAGO — Use of the GLP-1 receptor agonist semaglutide improved walking capability in patients with peripheral arterial disease (PAD) and type 2 diabetes (T2D), regardless of duration of diabetes, BMI, or glycemic control, a post-hoc analysis of phase 3 double-blind randomized STRIDE showed. “PAD remains a recalcitrant problem in people living with diabetes. We need […]
The post Semaglutide Shows Benefits for PAD Across T2D Subgroups first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-24 19:58:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8